CDMO Services
Cell & Gene Therapy
Partner focused. Patient driven.
Your global provider of tailored CGT solutions.
C3i has built a one-stop shop in the development chain of Cell & Gene Therapy.
We work closely with our clients to manufacture products destined for patients all over the world. C3i prides itself on delivering, on time, quality results on behalf of its clients and for patients, advanced cell and gene products that meet regulatory requirements around the world.
Our Purpose
We work with our clients to ensure we put patients first. We are driven to perform our best knowing that the cells in our hands may be the patient's only chance at survival.
Our People
We are dedicated and highly trained personnel with over 15 years of experience in cell therapy and cGMP manufacturing.
Our Facility
C3i is the only fully validated cGMP center in Canada compliant with FDA, EMA, and Health Canada regulations with commercial capacity.
Fully integrated in-house and on-site services to ensure seamless communication between all parties
We are a CDMO that develops, translates, and manufactures complex cell and gene therapies with a very high success rate. Our strength lies in working with our partners to advance the industry’s ability to bring cell and gene therapy research to market.
We are an extension of your team
C3i works as part of your team proudly blurring the lines between “you“ and “us” to the most desirable “we.” We are the CDMO for cell and gene therapy that fills the gap between your research and innovative patient therapies.
Read the latest news
-
Mar 24, 2025A Deep Dive into Flow Cytometry
Read MorePrecision-Driven Flow Cytometry: Advanced Technologies Ensuring Reliable Data for Complex Therapies. All flow cytometry assays performed in C3i are qualified and/or validated. Depending on the assays, three instruments are currently used: FACS Lyric, FACS Canto, or Accellix. During the qualification/validation, accuracy is verified using a known control (where reference values have already been established). Reproducibility […]
-
Mar 10, 2025C3i announces the promotion of Julie Artigalas to Senior Manager – Client Accounts
Read MoreC3i is pleased to announce the promotion of Julie Artigalas to the position of Senior Manager – Client Accounts. This promotion marks a key milestone in our ongoing commitment to delivering strategic support and high-quality service to our partners, and reflects the significant impact Julie has had on the management of our clinical projects. Holding […]
-
Feb 19, 2025C3i Center receives approval from the EMA to manufacture cell therapy products for the European market.
Read MoreC3i announces that it has obtained regulatory approval from the EMA (European Medicine Agency) to produce cell therapy treatments for the European market. The company received a certificate of Good Manufacturing Practice (GMP) compliance following an inspection of their Montreal facility by the European Medicines Agency. Therefore, C3i obtains a certificate of GMP (Good Manufacturing […]
Make great strides in your career at C3i
C3i offers a wide range of opportunities for you to contribute to our mission of advancing cell and gene therapy.